In the last 10 years, we have witnessed dramatic changes in the treatment of multiple myeloma that have provided hope and optimism to myeloma patients worldwide.

We have a better understanding of the biology of the disease and an array of approved and investigational new drugs with excellent clinical activity.

Importantly, we have also come to the realization that myeloma is not one genetically distinct disease, but a clinical condition with many distinct molecular subtypes. Indeed, there are subtle differences …